/content/dam/www/people-profile-photos/d/ann-dahlberg/ann-dahlberg-d.jpg
Dahlberg
Ann Dahlberg, MD

Ann Dahlberg, MD

  • Associate Professor, Clinical Research Division, Fred Hutch
  • Medical Director, Pediatric Outpatient Transplant Clinic , Fred Hutch/Seattle Children’s Hospital
  • Affiliate Investigator, Translational Science and Therapeutics Division, Fred Hutch
  • Associate Professor, Pediatric Hematology/Oncology, University of Washington
  • Associate Professor, Department of Pediatrics, Division of Hematology and Oncology, University of Washington
  • Attending Physician, Seattle Children’s Hospital
206.667.6932
206.667.2324

Background

Dr. Ann Dahlberg is a clinical researcher who studies cord blood transplantation, a form of blood stem cell transplant. She also has an interest in strategies for preventing leukemia relapse after patients receive transplants. She runs clinical trials in cord blood transplantation. In addition to this research focus, she runs trials in supportive transplant care, including the treatment of infections and the prevention of transplant-associated complications. As a physician, she cares for children receiving blood stem cell transplants. She provides care early after transplant, and she runs a clinic at Seattle Children’s focused on longer-term post-transplant care for patients with leukemia.

Education

University of Washington School of Medicine, Fellowship (2008-2011)

University of Washington School of Medicine, Residency (2005-2008)

Harvard Medical School, Boston, MA, MD (2005)

Stanford University, Stanford, CA, BS (2001)

Research Interests

Dr. Dahlberg is in interested in cord blood transplantation and runs clinical trials in this setting. She also has an interest in developing and implementing strategies to prevent relapse after transplant in patients with leukemia.

Find an Active Clinical Trial Led by Dr. Dahlberg

Stories

All news
Dr. Stanley Riddell awarded Burke O'Reilly Family Endowed Chair in Immunotherapy Inspired by child's life-threatening illness, family's gift funds development of next-gen therapies November 25, 2020